The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

Zhaoqing Tang, Yan Wang, Dan Liu, Xuefei Wang (), Chen Xu, Yiyi Yu, Yuehong Cui, Cheng Tang, Qian Li, Jing Sun, Qian Zhang, Yuan Ji, Guifen Ma, Haojie Li, Zhenbin Shen, Kuntang Shen, Rongrong Zheng, Zhiguo Hou, Tianshu Liu (), Jiping Wang () and Yihong Sun ()
Additional contact information
Zhaoqing Tang: Zhongshan Hospital, Fudan University
Yan Wang: Zhongshan Hospital, Fudan University
Dan Liu: Zhongshan Hospital, Fudan University
Xuefei Wang: Zhongshan Hospital, Fudan University
Chen Xu: Zhongshan Hospital, Fudan University
Yiyi Yu: Zhongshan Hospital, Fudan University
Yuehong Cui: Zhongshan Hospital, Fudan University
Cheng Tang: Zhongshan Hospital, Fudan University
Qian Li: Zhongshan Hospital, Fudan University
Jing Sun: Zhongshan Hospital, Fudan University
Qian Zhang: Zhongshan Hospital, Fudan University
Yuan Ji: Zhongshan Hospital, Fudan University
Guifen Ma: Zhongshan Hospital, Fudan University
Haojie Li: Zhongshan Hospital, Fudan University
Zhenbin Shen: Zhongshan Hospital, Fudan University
Kuntang Shen: Zhongshan Hospital, Fudan University
Rongrong Zheng: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Zhiguo Hou: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Tianshu Liu: Zhongshan Hospital, Fudan University
Jiping Wang: Brigham and Women’s Hospital, Harvard Medical School
Yihong Sun: Zhongshan Hospital, Fudan University

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant combination in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Thirty-six patients received capecitabine 850 mg/m2 twice daily and simultaneous radiotherapy for 5 weeks, sandwiched by a 21-day cycle of oxaliplatin 130 mg/m2 (day 1) plus capecitabine 1000 mg/m2 twice daily (days 1–14), respectively, followed by surgery. Camrelizumab 200 mg (day 1) was given for 5 cycles since initiating chemotherapy. Primary endpoint was pathological complete response (pCR, ypT0) rate. Secondary endpoints included total pCR (tpCR, ypT0N0) rate, major pathological response (MPR,

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-34403-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34403-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-34403-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().